Sunday, 20 September 2026European Markets

70% Drop In TERACT BS Stock: Should It Be Time To Sell?

Loading stream...
(vianews) - teract bs (terbs.pa), listed on the cac 40 index, experienced an astonishing 70% fall from eur0.10 to eur0.03 by 16:19 est on monday; this drop occurred despite overall cac 40 index rising 1.32% to eur7,324.80 following an upward trend. teract bs's last closing price was eur0.10, which is below its 52-week high of eur0.10. investors have noted this dip and are closely watching for signs that teract's financial health and business prospects might have worsened.

yearly analysis

based on its current stock price of eur0.03, teract bs has reached its 52-week low point over the last year, meaning that investors should carefully consider all relevant factors before making investment decisions in teract bs. it would also be wise to assess factors such as its financial health, industry trends, and overall market conditions prior to investing.

technical analysis

moving average analysis: teract bsteract bs's current stock price of eur0.06 falls significantly below both its 50-day and 200-day moving averages, both set at eur0.10 respectively, suggesting an imminent downward trend in its share price over short and long terms. investors may be alarmed at this trend as moving averages provide technical indicators of the stock's price trend and widening gaps between its current price and moving averages could suggest further downward movement of its share price. it should be remembered, however, that moving averages are only one indicator used to analyze a stock's performance; other considerations like fundamental analysis as well as market conditions must also be taken into account when analyzing performance of any particular stock. more news about teract bs (terbs.pa).
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com